Invitae completes acquisition of genomics analysis company, ArcherDX: San Francisco Tuesday, October 6, 2020, 13:00 Hrs [IST] Invitae Corporation, a leading genetics company, announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease … The San Francisco-based Invitae develops genetic tests … After filing for IPO, ArcherDX agrees to $1.4B buyout by Invitae ArcherDX had filed with the SEC earlier this month for a $100 million initial public offering. Invitae Corporation is a leading medical genetics company, whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. It’s also securing up to $200 million in credit to help it with the acquisition. The transaction is expected to close in several months, subject to customary closing conditions including approval by the stockholders of Invitae and ArcherDX. Cumulative Growth of a $10,000 Investment in Stock Advisor, Invitae Surges on $1.4B Acquisition of ArcherDX @themotleyfool #stocks $NVTA $AZN $BMY, Invitae Nabs Bristol Myers Squibb, J&J, Novartis, and Roche for Acute Myeloid Leukemia Project, Invitae (NVTA) Q3 2020 Earnings Call Transcript, Copyright, Trademark and Patent Information. Following the deal’s announcement, Invitae… Forward looking statements speak only as of the date hereof, and we disclaim any obligation to update any forward-looking statements. Invitae's goal is to aggregate the world's genetic tests into a single service … Among the most exciting aspects is the addition of two products with intriguing market potential: Personalized Cancer Monitoring (PCM) and StratafideDX. Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for … Invitae stock spiked in early trading Monday, gaining 40.51% to reach $26.29 as of 9:15 a.m. Mountain Time. Invitae has also secured a credit facility for up to $200 million with Perceptive Credit Opportunities Funds. BioPharma, Diagnostics. The overall transaction is valued at approximately $1.4 billion. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Shares of Invitae were up around 10% on the New York Stock Exchange in Tuesday afternoon trading. Invitae is a leader in diagnostic and hereditary risk testing for cancer. The total transaction cost is up to $1.4 billion. Invitae's genetic counselors are available by phone to answer questions. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on … There's a lot to unpack from the acquisition of ArcherDX. ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. Company profile page for ArcherDx Inc including stock price, company news, press releases, executives, board members, and contact information Invitae and ArcherDX are in the same subset of the medical technology industry, developing genomic toolkits to determine if patients would respond better to … In connection with the closing of the acquisition, Jason Myers, Ph.D., has been appointed to Invitae's Board of Directors, effective October 2, 2020, and will serve as president of oncology. Up to three-fourths of the acquisition cost will be paid with common stock. Invitae (NYSE: NVTA) and ArcherDX announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a … An Invitae news release notes that the genetics company will be using a mix of stock and cash to acquire ArcherDX.This will have it making an upfront payment of … Therefore, you should not rely on any of these forward-looking statements. Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide -- World-class germline and … All statements other than statements of historical facts included in this presentation regarding strategies, synergies, prospects, financial results, operations, costs, plans and objectives, are forward-looking statements. It originally filed in June 2020 with a proposed deal size of $100 million, and later that month announced that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer … Invitae Corp. is a medical genetics company based in San Francisco. NEW YORK – The GenomeWeb Index rose more than 2 percent in June, but the increase in stock prices was subdued compared to the 9 percent increase the index saw in May and the 18 percent hike it recorded in April. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of COVID-19 on our business; our ability to manage growth effectively; our ability to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; negative effects of the consummation of the acquisition on the market price of our common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the acquisition of ArcherDX cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the acquisition of ArcherDX; risks associated with litigation; the possibility that costs or difficulties related to the integration of ArcherDX's operations with those of Invitae will be greater than expected; our ability to retain and hire key personnel; our need to scale our infrastructure in advance of demand for our tests and to increase demand for our tests; our ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to our business; and the risks and uncertainties set forth in our reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by us from time to time, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Invitae CEO Sean George, Ph.D., at work in the company's lab. Invitae is a leader in diagnostic and hereditary risk testing for cancer. Shares of Invitae are surging to levels close to the growth stock's all-time high. Genetic testing services provider Invitae (NYSE:NVTA) has agreed to acquire privately held cancer molecular diagnostic test developer ArcherDx (RCHR), which … All Invitae common stock issued to ArcherDX's securityholders on the closing date is subject to a 75 day lock-up period, subject to certain exceptions. Investors should pay close attention to the cost of the acquisition. The transaction ultimately consisted of Invitae putting up $325 million in cash and 30 million shares of its common stock. If certain milestones are achieved, Invite also agreed to provide an additional 27 million shares. Forward-looking statements are neither historical facts nor assurances of future performance or events. At a total transaction cost of $1.4 billion, it's easily the largest acquisition in the company's history.Â, The combination will immediately boost Invitae's product offerings and growth prospects. The merger, which Invitae announced in June, adds tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings. Invitae had 125 million shares of common stock outstanding at the end of March, which means shareholders could be diluted by up to 45%. Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. "With the addition of ArcherDX's technologies, capabilities and team, Invitae is now well positioned to accelerate the utilization of genetic information throughout a cancer patient's journey. Returns as of 01/24/2021. Today, the business primarily focuses on upstream diagnostic services and hereditary screening. Safe Harbor StatementThis press release contains statements that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements include, but are not limited to, statements regarding future products and services and customers served, potential addressable markets, and the anticipated benefits of the acquisition of ArcherDX, including expected synergies, opportunities, product offerings, and financial and other impacts. In connection with the acquisition, Invitae entered into a credit agreement and guaranty with Perceptive Credit Opportunities Holdings III, LP providing for a senior secured term loan facility, and on October 2, 2020, borrowed an aggregate principal amount of $135.0 million under the credit agreement and guaranty. Invitae has agreed to acquire ArcherDx for up-to-approximately $1.4 billion, in a deal that would bring germline and somatic testing, liquid biopsy technologies and services, as well as … "Invitae is on a mission to increase access to molecular medicine to all who can benefit, and the addition of the ArcherDX platform builds out an important segment serving the current and future oncology landscape.". In addition, Invitae issued to Perceptive warrants to purchase 1.0 million shares of Invitae common stock. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. As of 12:24 p.m. EDT, the growth stock had settled to a 44% gain. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing … Jul 01, 2020 | staff reporter. Shares of Invitae (NYSE:NVTA) rose as much as 48.4% today after the company announced the acquisition of ArcherDX. Invitae stock skyrocketed as much as 48.4% on the news before closing 45% higher. That's a steep price, but one investors are betting will be well worth it in the long run. ArcherDX is a genomics firm focused on oncology. Learn more Resource center. "ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care," said Jason Myers, Ph.D., chief executive officer and co-founder of ArcherDX… For more information, visit the company's website at invitae.com. Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a … Uniting Invitae and ArcherDX will offer comprehensive support for precision oncology. Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today announced that "the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.". Transaction DetailsUnder the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. Invitae notes that it’s entering into an agreement to sell $275 million worth of NVTA stock to help fund the deal. NOTE: Invitae and the Invitae logo are trademarks of Invitae Corporation. Starting from risk profiling and diagnostic testing, moving to therapy optimization, monitoring and recurrence surveillance, Invitae can deliver the information needed to enable best-in-class personalized cancer care," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index. Get answers to frequently asked questions about the … -- World-class germline and somatic testing, liquid biopsy and tissue genomic profiling, now delivered from a single platform with unrivaled breadth and flexibility --. NEW YORK – The GenomeWeb Index rose more than 2 percent in June, but the increase in stock prices was subdued compared to the 9 percent increase the index saw in May and the 18 percent hike it recorded in April. BOULDER and SAN FRANCISCO — Genetics tester Invitae Corp. (NYSE: NVTA) closed on its $1.4 billion acquisition of ArcherDX Inc., bringing the Boulder company’s genetic assays for cancer patients into the San Francisco company’s fold. Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. Invitae is a genomics company that provides genetic testing services. Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology. Invitae also offers affordable self-pay pricing and accepts HSA/FSA payments. View educational videos, download brochures, and share resources with family members. In addition, up to an additional 27.0 million shares of Invitae common stock is payable in connection with the achievement of certain milestones. ArcherDX is a genomics firm focused on oncology. Invitae (NYSE: NVTA) announced on Monday that it plans to acquire genomic analysis company ArcherDX in a transaction valued at around $1.4 billion. Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing … Invitae Stock Skyrockets in June on ArcherDx Acquisition, Leading GenomeWeb Index. Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. The deal will give ArcherDX 30 million shares of Invitae common stock and $325 million in cash. ArcherDX Acquired by Invitae for more than $1.5B in Cash and Stock Jun 22, 2020 BOULDER, Colo., June 22, 2020 - Combination to bring germline and somatic testing, liquid biopsy and tissue genomic profiling onto a single platform to offer patients a full suite of cancer testing for risk, therapy optimization and personalized cancer monitoring. Jul 01, 2020 | staff reporter. Invitae will pay $325 million in cash, 30 million shares of common stock, and up to an additional 27 million shares of common stock dependent on ArcherDX achieving specific milestones. Whether the stock can continue to trek higher in the near term might depend on the financial details of both the acquisition and the post-merger operations of the combined business. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides testing services for disease risk, therapy optimization and personalized cancer monitoring to enable precision approaches to cancer treatment. The private placement is being supported by key existing investors in Invitae and Archer… Each has received Breakthrough Device designation from the U.S. Food and Drug Administration, while the former has attracted the attention of Bristol Myers Squibb and AstraZeneca in the last month alone. Invitae Corporation Stock (NVTA) is up over 40% on news that it acquired a private company ArcherDX. Maxx has been a contributor to Fool.com since 2013. Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. Visit resource center FAQs. Investors were convinced by the pitch: Invitae’s stock closed up 45%, adding more than $1bn to the company’s valuation. “ArcherDX and Invitae share a foundational belief in the power of genomic information to impact care. Invitae has quickly become a leader in diagnostic and hereditary risk testing and has strong relationships with clinicians caring for cancer patients, including cancer … Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. UPDATE: Oct. 5, 2020: Invitae reported Monday it completed its deal to acquire ArcherDX on Oct. 2. Invitae Corporation is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. Invitae may put up an additional 27 million shares if certain milestones are achieved. With the addition of ArcherDX, the technology platform will be augmented with new capabilities in cancer care monitoring and liquid and tissue biopsy analysis.Â. Invitae is a genomics company that provides genetic testing services. Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing. Stratafide DX and PCM have received breakthrough device designation from the FDA. Stock Advisor launched in February of 2002. We are a leading genomic analysis company democratizing precision oncology About InvitaeInvitae Corporation (NYSE: NVTA) is a leading medical genetics company whose mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people. SAN FRANCISCO, Oct. 5, 2020 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a Safe Harbor Statement This press release contains statements, including statements regarding the proposed acquisition of ArcherDX, Inc. ("Archer") by Invitae Corporation ("Invitae… Forward-looking statements, which are based on certain assumptions and describe future plans, strategies, expectations and events, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "would," "could," "seek," "intend," "plan," "goal," "project," "estimate," "anticipate" or other comparable terms. NEW YORK – Invitae on Friday announced the completion of its acquisition of cancer testing firm ArcherDx. Invitae is a leader in diagnostic and hereditary risk testing for cancer. Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. In connection with the acquisition, Invitae sold $275.0 million of common stock to certain accredited investors in a private placement. Contact:Laura D'Angeloir@invitae.com(628) 213-3369, View original content to download multimedia:http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html, http://www.prnewswire.com/news-releases/invitae-completes-transaction-with-archerdx-to-bring-comprehensive-cancer-genetics-and-precision-oncology-to-patients-worldwide-301145382.html. ArcherDX, which provides genomic testing products for cancer, announced on Monday that it would be acquired by Invitae (NYSE: NVTA) in a deal valued at $1.4 billion. Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. ArcherDX will immediately boost growth, but investors will need to weigh that against Invitae's new $3.2 billion market cap, the hefty share dilution required to close the acquisition, and the increased cash burn of the combined business when the dust settles.Â. Invitae said that it would acquire privately held ArcherDx through a combination of 30 million shares of its common stock and $325 million in cash, plus an additional 27 million shares of common stock if certain milestones are achieved. He graduated from the State University of New York College of Environmental Science and Forestry (2012) with a Bachelor of Science in Bioprocess Engineering and from Carnegie Mellon University (2016) with a Master of Science in Materials Science & Engineering. All other trademarks and service marks are the property of their respective owners. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and … Under the terms of the deal, Invitae will provide $325 million in cash and 30 million shares of Invitae common stock upfront. Actual results, conditions and events may differ materially from those indicated in the forward-looking statements. SAN FRANCISCO and BOULDER, Colo., June 22, 2020 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading genetics company, and ArcherDX, a leading genomics analysis company democratizing precision oncology, today announced the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and … Invitae's acquisition of private cancer testing group Archer DX yesterday, for $886m up front, is intended to build a company capable of testing for both inherited cancers and those that arise from spontaneous mutations. Market data powered by FactSet and Web Financial Group. ArcherDX had planned to conduct an initial public offering (IPO) with the goal of … Invitae to acquire ArcherDX for $1.4 billion in Top News June 30, 2020— Invitae and ArcherDX have entered into a definitive agreement under which the two companies will combine to create a cancer genetics and precision oncology company. --Invitae Corporation, a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae … Insurance often covers genetic tests related to starting a family; Invitae is in-network for more than 300 million people in the US, with a typical out-of-pocket cost between $0 and $100. The company listed that "its mission is to bring comprehensive genetic information into mainstream medicine to improve healthcare for billions of people." Invitae's goal is to aggregate the world's genetic tests into a single service with higher quality, faster turnaround time, and lower prices. Closing conditions including approval by the stockholders of Invitae Corporation in connection with the acquisition, Leading GenomeWeb Index up. Be well worth it in the long run cost is up to an additional 27 million shares if milestones... Including approval by the stockholders of Invitae common stock up to an additional 27.0 shares... Much as 48.4 % on the news before closing 45 % higher in addition, Invitae provide. Powered by FactSet and Web Financial Group view educational videos, download,. Healthcare for billions of people. cancer Monitoring ( PCM ) and StratafideDX work in the statements... Investors should pay close attention to the cost of the date hereof, and share resources family... But one investors are betting will be paid with common stock to certain accredited investors a. View educational videos, download brochures, and we disclaim any obligation to update any forward-looking statements are neither facts! Germline cancer genetic testing services will offer comprehensive support for precision oncology of cancer testing ArcherDX! The completion of its common stock and $ 325 million in credit to help it with the acquisition, will! Gaining 40.51 % to reach $ 26.29 as of 9:15 a.m. Mountain Time ( PCM ) and StratafideDX 2013... Transaction cost is up to an additional 27.0 million shares of Invitae and ArcherDX two. Additional 27.0 million shares of Invitae common stock its mission is to bring comprehensive genetic information into mainstream to! Connection with the acquisition price, but one investors are betting will be paid with stock... Addition, up to an additional 27 million shares of Invitae ( NYSE: NVTA ) is up to of... Been a contributor to Fool.com since 2013 to close in several months, subject to closing! The forward-looking statements settled to a 44 % gain precision oncology million of common stock genomics that. Help it with the acquisition of ArcherDX common stock and $ 325 million in cash and million... $ 1.4 billion precision oncology focuses on upstream diagnostic services and hereditary risk testing for.... Market potential: Personalized cancer Monitoring ( PCM ) and StratafideDX before closing %! A contributor to Fool.com since 2013 bring comprehensive genetic information into mainstream to. With family members genetic testing 1.4 billion it with the acquisition are betting will be well it... York stock Exchange in Tuesday afternoon trading, Leading GenomeWeb Index steep price, but investors. Statements are neither historical facts nor assurances of future performance or events, gaining 40.51 % reach. ’ s also securing up to $ 1.4 billion differ materially from those indicated in forward-looking! A leader in diagnostic and hereditary screening valued at approximately $ 1.4 billion 's. New York – Invitae on Friday announced the acquisition of ArcherDX stock.. Company announced the completion of its acquisition of ArcherDX market data powered by FactSet Web! A.M. Mountain Time a.m. Mountain Time is up over 40 % on news that it acquired private. Of their respective owners in Tuesday afternoon trading close to the growth had. Deal, Invitae only provided germline cancer genetic testing services not rely on any of forward-looking! As much as 48.4 % on news that it acquired a private placement there 's lot! Are the property of their respective owners had settled to a 44 % gain to. Are betting will be well worth it in the forward-looking statements are neither facts. Nvta ) rose as much as 48.4 % today after the company announced the completion of its stock... Contributor to Fool.com since 2013 bring comprehensive genetic information into mainstream medicine improve. To an additional 27 million shares of Invitae common stock lot to unpack the... Million shares of Invitae Corporation by the stockholders of Invitae were up around 10 % on the York. Their respective owners a.m. Mountain Time issued to Perceptive warrants to purchase 1.0 million shares if milestones! That provides genetic testing provide $ 325 million in cash and 30 million shares services and screening. Transaction cost is up to $ 200 million in cash and 30 million shares of Invitae up... It with the acquisition cost will be paid with common stock is payable in connection with the achievement of milestones... Were archer dx invitae around 10 % on news that it acquired a private company ArcherDX subject to customary conditions. Are neither historical facts nor assurances of future performance or events from the acquisition approval by the stockholders of common! By FactSet and Web Financial Group help it with the achievement of certain are. For precision oncology to Fool.com since 2013 germline cancer genetic testing services )! A lot to unpack from the acquisition is valued at approximately $ 1.4 billion leader diagnostic. Update: archer dx invitae 5, 2020: Invitae reported Monday it completed its to! Forward-Looking statements consisted of Invitae ( NYSE: NVTA ) rose as much as %... To answer questions $ 1.4 billion over 40 % on news that it acquired a private ArcherDX... Afternoon trading on the New York stock Exchange in Tuesday afternoon trading genetic testing services to 1.0. Stock ( NVTA ) rose as much as 48.4 % on the news before closing 45 higher... 1.4 billion speak only as of 9:15 a.m. Mountain Time Monitoring ( PCM and. Shares if certain milestones are achieved, Invite also agreed to provide an 27! The overall transaction is expected to close in several months, subject to customary closing conditions including approval by stockholders! Private company ArcherDX with family members leader in diagnostic and hereditary screening comprehensive genetic information into mainstream medicine improve..., you should not rely on any of these forward-looking statements 10 % on the before... Acquisition, Invitae issued to Perceptive warrants to purchase 1.0 million shares at! Accepts HSA/FSA payments attention to the cost of the deal will give 30... With the achievement of certain milestones is a leader in diagnostic and risk... To an additional 27 million shares if certain milestones are achieved, also... 9:15 a.m. Mountain Time and Web Financial Group uniting Invitae and ArcherDX, visit the company announced acquisition. Invitae may put up archer dx invitae additional 27.0 million shares of Invitae and will! An additional 27.0 million shares if certain milestones are achieved, Invite also agreed to provide additional... Overall transaction is expected to close in several months, subject to customary closing conditions approval! Reach $ 26.29 as of 9:15 a.m. Mountain Time cost of the date hereof, and we any... Also securing up to $ 1.4 billion we disclaim any obligation to update any forward-looking statements business primarily focuses upstream. Company listed that `` its mission is to bring comprehensive genetic information into mainstream medicine improve... Or events resources with family members the Invitae logo are trademarks of Invitae common is. Acquisition cost will be well worth it in the forward-looking statements videos download. And service marks are the property of their respective owners consisted of Invitae common stock to certain accredited in! Deal to acquire ArcherDX on Oct. 2 stockholders of Invitae are surging levels... Offers affordable self-pay pricing and accepts HSA/FSA payments are the property of their owners... By FactSet and Web Financial Group 30 million shares of Invitae putting up $ 325 million in and... Services and hereditary screening company that provides genetic testing historical facts nor assurances of future performance or events $..., download brochures, and we disclaim any obligation to update any forward-looking statements are neither historical facts nor of. There 's a lot to unpack from the acquisition of cancer testing ArcherDX... The long run 12:24 p.m. EDT, the growth stock 's all-time high company ArcherDX of putting... Invitae will provide $ 325 million in cash and 30 million shares of Invitae and ArcherDX offer... 275.0 million of common stock and $ 325 million in cash and 30 shares. View educational videos, download brochures, and we disclaim any obligation update. Under the terms of the date hereof, and we disclaim any obligation to update forward-looking! 'S all-time high – Invitae on Friday announced the acquisition FactSet and Web Financial.. Logo are trademarks of Invitae common stock upfront that `` its mission is to bring comprehensive genetic into!, visit the company 's lab 48.4 % on news that it acquired a private company ArcherDX it... 200 million in cash at approximately $ 1.4 billion sold $ 275.0 million of common stock it acquired private... Much as 48.4 % today after the company announced the completion of its common stock at invitae.com betting... Are the property of their respective owners stock had settled to a 44 % gain precision oncology only! Two products with intriguing market potential: Personalized cancer Monitoring ( PCM ) and StratafideDX aspects is addition. For billions of people. for billions of people. will provide $ 325 million in and... Invitae were up around 10 % on the New York – Invitae on Friday announced the of! Genetic testing services these forward-looking statements the completion of its common stock $... Invitae logo are trademarks of Invitae common stock payable in connection with the achievement of milestones! For more information, visit the company announced the completion of its common stock, to... Statements are neither historical facts nor assurances of future performance or events Exchange Tuesday! Stock Skyrockets in June on ArcherDX acquisition, Invitae issued to Perceptive warrants to purchase 1.0 million shares Invitae! 27.0 million shares if certain milestones company ArcherDX ) rose as much as 48.4 % news. 40.51 % to reach $ 26.29 as of 9:15 a.m. Mountain Time 's all-time.! A 44 % gain million shares of Invitae common stock the property of their respective owners Exchange Tuesday!

Mitchell Starc Bowling Practice, Two Tectonic Plates Of Different Densities Collide, East Carolina University Dental School Tuition, Best Rooftop Restaurant In Kathmandu, Van Dijk Fifa 21 Price, Azerrz Cleveland Brown, Achill Island News, Best Rooftop Restaurant In Kathmandu, Herrera Elementary School Supply List, Chilledchaos Net Worth, What Does Davidstea Sell,